SESSION TITLE: Symptoms of Respiratory Disease Posters
SESSION TYPE: Poster Presentations
PRESENTED ON: Saturday, March 22, 2014 at 01:15 PM - 02:15 PM
PURPOSE: Cough is a very common symptom and may have a deep impact on quality of life both of children and adults, thus often requiring an empiric treatment with antitussive agents. Levodropropizine is a very well tolerated peripheral drug, while central cough suppressants (opioids and non opioids) may be associated with side effects that limit their use, especially in children. The aim of our two meta-analysis is to evaluate the overall comparative efficacy of levodropropizine in both pediatric and adult population.
METHODS: After comprehensive systematic literature search on main electronic databases (PubMed/MEDLINE, EMBASE, and Cochrane Library), we performed a first standardized meta-analysis of 4 controlled clinical studies of levodropropizine (3 vs. central antitussives and 1 vs. placebo) assessing efficacy cough outcomes, including a total of 780 children. We also performed a meta-analysis of 7 controlled clinical studies of Levodropropizine (5 vs. central antitussives and 2 vs. placebo) including 2633 patients, both children and adults. Main efficacy parameters were cough frequency, severity, and night awakenings.
RESULTS: The first meta-analysis of all standardized efficacy parameters, only in pediatric patients, showed a highly statistically significant difference in the overall antitussive efficacy in favor of Levodropropizine vs. control treatments (p = 0.001). The heterogeneity test for the efficacy outcome was not statistically significant (p=0.0619). Our second meta-analysis also showed a highly statistically significant difference in the overall antitussive efficacy in favor of levodropropizine vs. control treatments (p = 0.0044). The heterogeneity test for the efficacy outcome was not statistically significant (p=0.0856).
CONCLUSIONS: Our two meta-analysis indicate that Levodropropizine is an effective antitussive drug both in adults and children, with statistically significant better overall efficacy outcomes vs. central antitussives, in terms of reducing cough intensity, frequency and nocturnal awakenings.
CLINICAL IMPLICATIONS: These results further reinforce the favorable benefit/risk profile of Levodropropizine in the management of cough in pediatric and adult settings.
DISCLOSURE: Luigi Lanata: Employee: Medical Director Federico Saibene: Employee: Junior Medical Manager Michela Bagnasco: Employee: Medical Manager The following authors have nothing to disclose: Francesco De Blasio, Peter Dicpinigaitis, Alessandro Zanasi, Giovanni Fontana
No Product/Research Disclosure Information